placebo for risankizumab + risankizumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ankylosing Spondylitis (AS)
Conditions
Ankylosing Spondylitis (AS)
Trial Timeline
Jan 28, 2014 → Jul 25, 2016
NCT ID
NCT02047110About placebo for risankizumab + risankizumab
placebo for risankizumab + risankizumab is a phase 2 stage product being developed by AbbVie for Ankylosing Spondylitis (AS). The current trial status is completed. This product is registered under clinical trial identifier NCT02047110. Target conditions include Ankylosing Spondylitis (AS).
What happened to similar drugs?
20 of 20 similar drugs in Ankylosing Spondylitis (AS) were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04713592 | Phase 3 | Completed |
| NCT02047110 | Phase 2 | Completed |
Competing Products
20 competing products in Ankylosing Spondylitis (AS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab | Celltrion | Phase 1 | 29 |
| Infliximab | Celltrion | Phase 1 | 29 |
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 27 |
| adalimumab | Eisai | Phase 3 | 40 |
| Ixekizumab + Placebo + Adalimumab | Eli Lilly | Phase 3 | 32 |
| Tramadol /acetaminophen + Diclofenac | Johnson & Johnson | Approved | 35 |
| Golimumab + Placebo | Johnson & Johnson | Phase 3 | 40 |
| Golimumab | Johnson & Johnson | Approved | 43 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 2/3 | 38 |
| Adalimumab | AbbVie | Approved | 39 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 35 |
| Adalimumab | AbbVie | Pre-clinical | 26 |
| infliximab + Placebo | Merck | Phase 3 | 40 |
| Infliximab | Merck | Approved | 35 |
| Infliximab + Placebo + Naproxen | Merck | Phase 3 | 40 |
| Infliximab | Merck | Pre-clinical | 26 |
| Golimumab | Merck | Approved | 43 |
| Remicade | Merck | Approved | 43 |
| Remicade | Merck | Approved | 43 |
| Infliximab | Merck | Approved | 43 |